{"id":5057,"date":"2024-08-20T10:32:08","date_gmt":"2024-08-20T14:32:08","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/?post_type=perspectives&p=5057"},"modified":"2024-09-05T09:59:59","modified_gmt":"2024-09-05T13:59:59","slug":"oncology-clinical-trials-design-trends-in-biomarker-research","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/oncology-clinical-trials-design-trends-in-biomarker-research\/","title":{"rendered":"Oncology Clinical Trials: Design Trends in Biomarker Research"},"content":{"rendered":"

Oncology research has seen many changes and advances in recent decades, from new therapies in combination with backbone chemotherapy to novel treatments targeting malignancies, and compounds targeting specific disease biomarkers at the genetic mutation level. The latter approach has called to question large, relatively long clinical studies assessing the safety and efficacy of treatments against a large population defined at the tumor level. Rather, research at the subpopulation or biomarker level has garnered much more interest as targeted treatments are being developed.\u00a0<\/span>\u00a0<\/span><\/p>\n

This focus on subpopulations and biomarkers is changing how researchers approach clinical trials in oncology and helps resolve several issues with larger clinical trials. For example,<\/span> treatment effects may be diluted in a heterogeneous population, possibly resulting in an underpowered study<\/span>. Furthermore, <\/span>a large trial in a heterogeneous population may place patients for whom the drug is ineffective at risk of serious adverse events<\/span>. On the other hand, <\/span>restricting enrollment to a target subgroup without sufficient evidence may deny a large segment of the patient population access to a potentially beneficial treatment<\/span>. This blog post will briefly introduce two statistical approaches addressing the rise of more specific study populations: predefined subpopulation statistical analysis in the context of a larger trial population and population enrichment of the more promising subgroup within an ongoing study.<\/span>\u00a0<\/span><\/p>\n

Subpopulation Analysis<\/span><\/b>\u00a0<\/span><\/h2>\n

Subpopulation\u202ftesting and analysis is a phase III clinical trial design strategy in which a subset of the study population is selected based on patient characteristics that may be more likely to respond to the treatment under investigation. Identifying and analyzing specific\u202fsubpopulations\u202fallows the researcher to explore whether a treatment leads to different effects in a pre-designated subpopulation. A subpopulation can be defined by any stratification characteristic such as gender or geography, and in oncology clinical trials, specific biomarkers identified within a study population.<\/span>\u00a0<\/span><\/p>\n

This type of approach to clinical research has several significant benefits in Oncology studies<\/a>:<\/span>\u00a0<\/span><\/p>\n